HUMA Humacyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HUMA

Price (delayed)

$0.5657

Market cap

$157.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$143.22M

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 1
Highlights
The company's equity has surged by 169% QoQ
The revenue has soared by 159% YoY and by 5% QoQ
HUMA's EPS is up by 14% since the previous quarter but it is down by 13% year-on-year
HUMA's net income has dropped by 65% year-on-year
The gross profit has declined by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.humacyte.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of HUMA

HUMA stock price

How has the Humacyte stock price performed over time
Intraday
-2.93%
1 week
-0.75%
1 month
-11.91%
1 year
-66.72%
YTD
-41.1%
QTD
-27.51%

Financial performance

How have Humacyte's revenue and profit performed over time
Revenue
$2.12M
Gross profit
-$10.49M
Operating income
-$111.16M
Net income
-$96.74M
Gross margin
-494.6%
Net margin
-4,560.8%
The revenue has soared by 159% YoY and by 5% QoQ
HUMA's net income has dropped by 65% year-on-year
Humacyte's operating margin has surged by 61% YoY and by 7% QoQ
HUMA's net margin is up by 36% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does HUMA's price correlate with its fundamentals

Growth

What is Humacyte's growth rate over time

Valuation

What is Humacyte stock price valuation
P/E
N/A
P/B
4.02
P/S
62.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.52
HUMA's EPS is up by 14% since the previous quarter but it is down by 13% year-on-year
The company's equity has surged by 169% QoQ
HUMA's price to book (P/B) is 74% lower than its 5-year quarterly average of 15.7
The revenue has soared by 159% YoY and by 5% QoQ
The stock's price to sales (P/S) is 35% less than its last 4 quarters average of 98.9

Efficiency

How efficient is Humacyte business performance
Humacyte's return on assets has shrunk by 100% YoY
HUMA's return on invested capital has dropped by 80% year-on-year
HUMA's ROE has soared by 66% since the previous quarter
HUMA's return on sales is up by 31% year-on-year and by 6% since the previous quarter

Dividends

What is HUMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HUMA.

Financial health

How did Humacyte financials performed over time
HUMA's total assets is 29% higher than its total liabilities
HUMA's current ratio has soared by 153% YoY and by 58% from the previous quarter
The quick ratio has soared by 77% QoQ and by 28% YoY
HUMA's debt is 112% greater than its equity
The company's equity has surged by 169% QoQ
The debt to equity has dropped by 90% year-on-year and by 63% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.